Monthly Archives: May 2020

Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises

The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.

Read More

Genprex strikes deal with MD Anderson Cancer Center, adds to momentum in cancer fight

Austin startup a ripe M&A target for big pharma, one expert says

Read More

Genprex Issues April 2020 Shareholder Letter

Company provides updates on recent regulatory, clinical, operational, and business developments

Read More